both children and adults with ALL or AML without a well cally detect almost any rearrangement by Southern blotting of patient DNA. Each case with rearrangement of the MLL gene defined comparative group having no detected cytogenetic anomalies to establish prognosis or cytogenetic registries in was confirmed by identification of the rearrangement with at least two restriction enzymes. which different anomalies were compared in the absence of extensive clinical and therapeutic data. 4 In this study, in order to better define characteristics of 11q23 in adult AML, we performed a prospective analysis on Immunological phenotype newly diagnosed adult AML cases seen in a single center over a period of 10 years. AML cases with typical balanced 11q23
Beginning in 1986, patients had immunological phenotype as part of their initial evaluation. The presence of surface anomalies detected by conventional cytogenetics or, in more recent cases, MLL rearrangement detected by Southern blot, myeloid (CD13, CD14, CD15, CD33), lymphoid (CD10, CD19) or immature hematopoietic cell (CD34) markers and were compared to cases with unbalanced 11q23 chromosomal anomalies and cases with normal karyotype and no DR antigen was studied using indirect immunofluorescence. 41 MLL rearrangement when tested, treated according to the same chemotherapy protocols. This analysis led to the clinical confirmation of the existence of two different categories of
Patient therapy
AML with 11q23 breakpoint according to the presence of a typical balanced or unbalanced cytogenetic anomaly, Unless they were in poor general status or refused therapy, patients were treated according to ongoing first-line intensive confirming the different molecular pathogenesis of these two entities.
intercalating agent and cytosine arabinoside ± VP16 containing chemotherapy protocols. Patients aged less than 60 years were treated successively on LYLAM85 42 and LAM90 43 protocols. Patients aged more than 60 years were treated according Patients and methods to EORTC AML9, 44 AML11 45 and pilot AML13 46 protocols successively. All protocols included one or two courses of Patient population intensive consolidation. Approximately one-third of patients older than 60 years who achieved CR received maintenance All cases of adult (Ͼ15 years old) patients with AML diagnosed according to French-American-British Group (FAB) criusing low-dose Ara-C after one course of intensive consolidation. During this period of time, none of the therapeutic teria 38 referred to our center over a 10-year period, between January 1985 and December 1994, and having successful karprotocols differed according to patient karyotype. Patients aged less than 45 years with an HLA-identical family donor yotype at diagnosis showing 11q23 breakpoint or, more recently, a rearrangement of MLL gene evidenced by Southern were scheduled to receive allogeneic bone marrow transplantation following standard conditioning regimen. blot analysis were included in this study. They were compared to AML cases seen during the same period with normal karyotype at diagnosis and no MLL rearrangement when tested.
Statistical analysis
Leukemia cases with the typical balanced 11q23 breakpoint Chromosomal and molecular analyses detected by conventional cytogenetics were grouped with those with MLL rearrangement detected by Southern blot All AML patients seen at diagnosis in our institution during this period of time were scheduled to have cytogenetic analysis of (group 1) even when no karyotype was available or when the karyotype did not show 11q23 breakpoint, based on the likelitheir bone marrow leukemic cells during their initial evaluation, before any therapy, using standard RHG banding techhood of common molecular pathogenesis. These cases were compared to cases with unbalanced 11q23 chromosomal nique. Karyotypes were analyzed according to the International System for Cytogenetic Nomenclature. 39 A karyotype breakpoint and presumably no MLL rearrangement, as shown in the literature 25 and confirmed in the unique case tested here was considered normal when at least 15 normal mitoses were observed. 11q23 breakpoints as well as potentially associated (group 2). Acute myeloid leukemia cases with normal karyotype and no MLL gene rearrangement in the 29 cases tested structural anomalies were diagnosed when present in at least two mitoses. Anomalies of chromosome numbers were diagwere analyzed as a control group (group 3). Groups 1 and 2 were compared together and were independently compared nosed when present in at least three mitoses. MLL gene rearrangement has been studied retrospectively on frozen to control group 3 with regard to initial characteristics (past history of malignancy, toxic or radiation exposure, or myelodbone marrow samples obtained from patients diagnosed during the last 2 years using a conventional Southern blot techysplastic syndrome, organomegaly, blood counts, percent blasts in bone marrow, FAB subtypes, immunological markers, nique. High molecular weight DNA was extracted from mononuclear cells obtained after isolation by Ficoll-Hypaque serum enzymes) using Yate's corrected 2 or two-tailed Fisher's exact test when appropriate for discrete variables and centrifugation and containing at least 70% leukemic blasts. After digestion with HindIII and XbaI, DNA fragments were Mann-Whitney non-parametric test for continuous variables. The same parameters were analyzed for potential prognosseparated by electrophoresis in 0.8% agarose gel and transferred on to nylon filters according to standard procedure. tic significance for complete remission (CR) achievement, disease-free survival (DFS) and overall survival. Quantitative vari-MLL probe used in this study consists of reverse-transcribed polymerase chain reaction (RT-PCR)-amplified human RNA ables were treated as dichotomous in the analysis. Cut-off points used were the approximate median value for age and segments encompassing nucleotides 3560-3920 (exons 5, 6 and 7) on cDNA sequence. 40 The MLL gene spans 100 kb and hematological parameters and the upper limit of normal value for serum parameters. The 60-year cutpoint for age appeared contains at least 21 exons, however, 11q23 breakpoints are sufficiently clustered so that a single probe should theoreticlinically relevant as it was also the cutpoint used to assign 27 patients to therapeutic protocols designed for the elderly durtherapy with daunorubicin and conventional-dose Ara-C and died blastic 3 weeks after initiation of therapy. ing the 10-year study period. Since it is known that increasing age has a continuous negative prognostic impact in AML, it
In addition, 87 recently diagnosed cases of AML for whom frozen cellular material was available were analyzed by was checked that results of the statistical analyses would not have changed if age had been introduced in the analysis as a Southern blot for the presence of MLL gene rearrangement. Fourteen cases (16%) including 12/81 cases of de novo AML continuous variable.
Complete remission rates were compared using Yate's cor-(15%) and 2/6 cases of secondary AML (33%) were rearranged ( Figure 1) . Results of Southern blot analysis in different cytorected 2 and 95% confidence intervals (CI) on proportions of CR patients were calculated using the exact binomial formula.
genetic subgroups are indicated in Table 2 . Among six cases with balanced 11q23 breakpoint on karyotype tested, five Survival and DFS probabilities were calculated using the Kaplan and Meier product-limit estimate method and their were confirmed to have MLL rearrangement. The only case with no apparent MLL rearrangement (patient 6) had 95% symmetrical CI limit was calculated according to Greenwood's method. Survival curves were compared using the logt(6;11)(q27;q23) in only three of 20 mitoses examined. On the other hand, the only case with unbalanced translocation rank test. For analysis of survival and DFS of chemotherapytreated patients, patients undergoing allogeneic bone marrow tested, which had translocation with an unidentified partner chromosome in 18/20 mitoses (patient 28), had no MLL gene transplantation while in first CR were censored at the time of transplantation. Prognostic factors for CR were studied using rearrangement detected. A total of nine cases had MLL rearrangement detected in the absence of demonstrated balstepwise multiple logistic regression and prognostic factors for DFS and overall survival were studied using stepwise Cox's anced 11q23 cytogenetic anomaly ( Table 2 ). In one of these cases karotype was not attempted (patient 37), and another proportional hazard model. All variables that were statistically (two-tailed P Ͻ 0.05) predictive for CR achievement or surcase had unsuccessful karyotype (patient 38). Seven of these cases had an apparently successful karyotype not showing any vival and their interactions were proposed for entry in the stepwise multivariate model for prediction of the same end11q23 breakpoint, four of them normal (patients 39-42) and three showing other anomalies, including +13 in one (patient point. Goodness of fit of the models was tested using the likelihood ratio statistics. All computations were made using BMDP 43) and 7q monosomy in two (patients 44 and 45). These nine cases were pooled with the 19 cases with balanced 11q23 software (BMDP Statistical Software, Los Angeles, CA, USA).
chromosomal anomalies (group 1) for further analysis, based on probable similar molecular pathogenesis involving the MLL gene, after it was checked that there were no significant differResults ences in initial characteristics and evolution between these two subsets of patients. The 28 cases with balanced 11q23
Cytogenetic and molecular description of patient groups breakpoint/MLL rearrangement (group 1) were compared to the 17 cases with unbalanced 11q23 chromosomal anomaly (group 2) and both groups were compared to the 179/442 Over the 10-year study period, 442 adults with AML seen at diagnosis in our institution had a successful karyotype perforcases (40%) with normal karyotype and no MLL rearrangement in the 29 patients tested (group 3). med before any therapy, representing 89.5% of patients in whom a karyotype was attempted. Rearrangements involving 11q23 have been detected in 36 cases (8% of successful karyotypes) including 7/46 cases of secondary (therapyInitial characteristics and outcome of the different groups of patients related) leukemia (15%) and 29/396 cases of de novo leukemia (7%). This anomaly was related to a deletion in four cases, inversion in one, and translocation in 31 ( Table 1 ).
The three groups of patients, who were treated according to the same cytosine arabinoside and intercalating agent-based Nineteen patients had balanced chromosomal anomalies (group 1), including the case with inversion (patient 32) and intensive chemotherapy protocols, were compared two by two, with regard to clinical history, initial characteristics of 18 cases of balanced translocations. Among these 18 cases, two patients had t(4;11)(q21;q23) (patients 4, 5), two had the AML and outcome (Table 3) . There were significant differences in characteristics at prest(6;11)(q27;q23) (patients 6, 7), five had t(9;11)(p22;q23) (patients 8-12), one had t(11;15)(q23;q14) (patient 13), one entation between patients in groups 1 and 2 (Table 3) . AML with unbalanced 11q23 anomalies (group 2) occurred in older had t(11;17)(q23;q12) (patient 14), and seven had t(11;19) (q23;p13) (patients 15-21). Seventeen patients had unbalpatients (median age 62 vs 49 years, P = 0.07). They tended to be less frequently associated with previous exposure to anced 11q23 chromosomal anomalies (group 2), including three cases with t(1;11)(q21;q23) (patients 1-3), 10 cases with topoisomerase II-active drugs (five vs one case) and with M4/M5 FAB cytological subtypes (41 vs 64% of cases), translocations involving an unidentified partner chromosome (patients 22-31) and four cases with a deletion (patients 33-although this did not reach statistical significance. They always carried other chromosomal anomalies while only 10 36). The chromosomal breakpoint involved all mitoses (AA) in 20 cases including 10/19 cases with balanced anomalies evaluable patients with balanced 11q23 anomaly/MLL rearrangement did (P Ͻ 0.0001). Surface immunophenotype is and 10/17 cases with unbalanced anomalies, while residual normal mitoses (AN) were found in 16 cases. When several indicated in Table 4 , showing that patients with unbalanced anomalies had significantly more frequent expression of CD34 abnormal clones were present, the 11q23 breakpoint was present in the primary clone in all but one (patient 29) case.
antigen than patients with balanced anomalies (80 vs 35% of tested cases, P = 0.05). Furthermore, patients with unbalanced This patient was an 81-year-old woman with no previous history of drug exposure who presented with AML of FAB M4
anomalies had a significantly poorer prognosis than patients with balanced anomalies (Table 3) , including lower CR rate subtype with eosinophilia. Her initial WBC count was 127 × 10 9 /l. Karyotype showed inv(16)(p13q22) in the primary (18% CR, CI ranging from 4 to 43% vs 64% CR, CI ranging from 44 to 81%, P = 0.005), and shorter survival (median surabnormal clone. She was resistant to initial intensive chemo- vival 2.3 vs 9.6 months, P = 0.0005) (Figure 2a) , although in addition to the presence of an unbalanced anomaly (P = 0.0005), age Ͼ60 years (P Ͻ 0.0001), elevated liver there was no significant difference in DFS between the two groups ( Figure 2b ). All patients with an unbalanced 11q23 enzymes (P = 0.0008), hepatomegaly (P = 0.002), Ͼ30% blast cells in the peripheral blood (P = 0.008), the presence of anomaly have died and no patient survived more than 5 years in either of the two groups (Figure 2) . Among the 45 patients additional chromosomal anomalies (P = 0.02), splenomegaly (P = 0.008), and the lack of surface expression of CD15 in groups 1 and 2, factors predictive for a low CR rate in a univariate analysis included, in addition to the presence of an (P = 0.02). The presence of Ͼ30% blast cells in the peripheral blood was significantly associated with short DFS (P = 0.001). unbalanced anomaly (P = 0.005), age Ͼ60 years (P = 0.0003), hypercreatininemia (P = 0.005), surface expression of CD34
In a multivariate analysis taking into account potentially confounding prognostic factors, factors remaining significantly antigen by leukemic blasts (P = 0.006), the presence of a splenomegaly (P = 0.01), elevated serum liver enzymes predictive for achievement of CR were age (P Ͻ 0.001) and the presence of an unbalanced 11q23 anomaly (P = 0.03). (P = 0.01) and the presence of additional chromosomal anomalies (P = 0.03). Factors predictive for short survival included,
Factors predictive for short survival were hypercreatininemia
Figure 1
Rearrangement of MLL locus in acute myeloid leukemia. Ten micrograms of genomic DNA extracted from tumor DNAs (patients 8, 10, 12, 13, 18. 37-45) carrying a rearrangement of MLL and from normal peripheral blood lymphocytes (C) were digested with HindIII, electrophoresed through a 0.8% agarose gel, blotted on to a nylon membrane and hybridized to MLL probe. quent history of toxic exposure (P = 0.0003) particularly to topoisomerase II-active drugs, tended to be more frequently of M4/M5 FAB subtypes (P = 0.07), expressed more frequently HLA-DR antigen (P = 0.02) ( Table 3 ) and had shorter DFS with 0% of patients vs 20% (CI ranging from 11 to 29%) in the control group surviving disease-free at 5 years (P = 0.02) (Figure 2b ). Patients with unbalanced anomalies had more frequent splenomegaly (P = 0.009), lower WBC count (P = 0.04), diminished expression of CD15 (0.06) ( Table 4 ) and a much poorer prognosis for CR achievement (CR rate 18%, CI ranging from 4 to 43% vs 66%, CI ranging from 59 to 73%, P = 0.0001), survival (5-year survival 0 vs 19%, CI ranging from 12 to 26%, P Ͻ 0.0001) and DFS (5-year DFS 0 vs 20%, CI ranging from 12 to 28%, P = 0.01). In a multivariate analysis taking into account other factors of poor prognosis detected in the whole series of 224 patients, such as age Ͼ60 years, the presence of hepatosplenomegaly, adenopathy or other extramedullary involvement, elevated serum liver enzymes, balanced and unbalanced 11q23 anomalies were predictive of short survival (P = 0.04 and P Ͻ 0.0001, respectively) and short DFS (P = 0.06 and P = 0.03, respectively). It is note-(P = 0.01), the presence of an unbalanced 11q23 anomaly worthy that five patients with balanced 11q23 anomaly/MLL (P = 0.02), and age Ͼ60 years (P = 0.03). No factor remained rearrangement underwent HLA-identical allogeneic bone significantly predictive for DFS. marrow transplantation from a family donor while in first CR: When compared to the control population of patients with all of them died, four from leukemic relapse and one from normal karyotype and no MLL rearrangement when tested (Table 2) , patients with balanced anomalies had more fregraft-versus-host disease. Numbers between brackets indicate the number of patients exposed to agents targeting topoisomerase II: all these patients were exposed to intercalating agent; one patient was exposed, in addition, to VP16 (etoposide). Other patients were exposed to radiotherapy alone (four patients including one in group 1 and one in group 2) or alkylating agents (two patients in group 3 
Discussion
includes only five cases with inv/del(11q23), none of which were studied by Southern blot, therefore not allowing us to determine whether this is also true in adult AML. However, This study confirms the frequency of 11q23 breakpoint in newly diagnosed adult patients with AML and the existence the different clinical pattern observed in patients with unbalanced 11q23 anomalies by comparison with balanced anoof two molecular entities according to the balanced or not character of the chromosomal anomaly, only balanced anomalies together with the lack of MLL rearrangement in the only case of unbalanced anomaly tested could also point to malies being associated with MLL rearrangement. In addition, we show that these two subgroups of patients have different a different, perhaps MLL-unrelated, pathogenic entity of unbalanced cases in our study. initial characteristics and outcome, supporting the existence of different pathogenetic mechanisms at the molecular level.
Our clinical study, comparing cases with typical balanced 11q23 breakpoint or MLL rearrangement with that of cases The overall frequency of detection of 11q23 breakpoint by conventional cytogenetics in our patients tended to be higher with unbalanced 11q23 breakpoint show that they have very different initial characteristics and outcome, confirming the than that described in other series of de novo and secondary adult AML, with proportions of patients presenting with this probable existence of different molecular mechanisms of leukemogenesis in these two groups of patient. Initial characteranomaly ranging from 2 to 4.2% in de novo AML 4, 7, 27, 47, 48 and from 7.1 to 10% in secondary AML. 4, 7, 12 This could be istics of our patients with typical balanced 11q23 anomalies were very similar to those described in the literature, including due to the frequency of M4/M5 FAB subtypes in our series of patients, since association of this anomaly with these FAB association with previous exposure to topoisomerase II-active drugs, 14-17 young age of occurrence, and predominant M4/M5 subtypes has been largely confirmed, particularly in balanced translocations. 4, 29, 30, 36 However, association of 11q23 ano-FAB subtypes. [8] [9] [10] 27, 29, 30 On the other hand, patients with unbalanced anomalies were older, tended to be less fremaly with these particular cytological subtypes did not reach statistical significance in our group of patients, although 64% quently associated with previous exposure to topoisomerase II-targeting drugs and to be less frequently of M4/M5 cytologof cases of balanced anomaly were of M4/M5 FAB subtype. Occurrence of MLL rearrangement in non-M4/M5 FAB subical subtype, more frequently expressed the CD34 surface antigen, always had additional chromosomal anomalies and types, particularly M1, has been described, mainly in elderly patients. 49 The study of MLL gene rearrangement by Southern were of considerably poorer prognosis. The pejorative outcome was not uniquely explained by the unfavorable initial blot allowed detection of an even higher proportion of cases with MLL rearrangement including eight cases with no 11q23 characteristics, including the association of other cytogenetic anomalies, since the presence of an unbalanced 11q23 anoanomaly detected by conventional cytogenetics, as found in other series where the rearrangement was detected by Southmaly remained a factor of poor prognosis in a multivariate analysis taking into account all these potentially confounding ern blot 50 or FISH. 51 Cases with cytogenetically normal chromosome 11 have been shown frequently to involve a partial variables among our 45 patients with 11q23 anomaly or MLL rearrangement. To our knowledge, no other study directly duplication of MLL gene, 52 and appear often to be associated with trisomy 11 on karyotype, 50, 52 although this anomaly was compared initial characteristics and outcome of patients with balanced and unbalanced 11q23 anomalies. However, in one not observed in our cases. The 16% MLL rearrangement detected here appears higher than the 6.2% found in another large series of adult patients with 11q anomalies, the presence of additional chromosomal anomalies appeared of poor progseries 37 and might represent an overestimation since there is a potential bias related to the retrospective analysis of cases nosis. 7 Nevertheless, in this report, additional chromosomal anomalies were associated with previous exposure to cytoselected by the availability of frozen material. Our cases tested by Southern blot had significantly higher initial white blood toxic agents, which was not the case in our patients. In our series, previous exposure to topoisomerase II-active drugs cell counts than patients tested by conventional cytogenetics alone, although their other initial characteristics and evolution often resulted in isolated balanced translocation, as described by others. 14, 17 In one series of patients with infant ALL, 53 the were not significantly different. Overall, the frequency of 11q23 abnormality in cases that were studied by molecular existence or not of MLL rearrangement in patients with an 11q23 breakpoint appeared related to initial characteristics biology indicates that this rearrangement is probably the most frequent single genetic abnormality in adult AML, although and outcome, patients with no MLL rearrangement having lower WBC count, as observed in our patients, but a better not as frequent as in infant leukemias. 8, 9, 30 In our cases analyzed by Southern blot, MLL rearrangement was detected in prognosis, unlike in our series. Separate comparisons of each of our two groups of patients all but one case, presenting a balanced translocation classically found in AML, such as t(9;11) (three cases), t(11;15) and with a control group of 179 similar patients with normal karyotype and no MLL rearrangement when tested together with t(11;19) (one case each). The lack of detection of MLL rearrangement in one patient presenting with t(6;11) is unexa multivariate analysis of prognostic factors among the 224 patients involved in this study confirm the very poor prognosis pected. However, in this case, the cytogenetic anomaly was present in only 3/20 mitoses and this could be below the of unbalanced 11q23 chromosomal breakpoints independently of other characteristics. In addition, these analyses threshold of detection of a MLL rearrangement by Southern blot analysis. in this particular study. A third study 30 included 17 patients firmed previous molecular analysis, 25 indicating that unbal- 
